date,title,source
Oct-22-18,"Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist",PR Newswire
Nov-13-18,Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies,PR Newswire
Nov-14-18,Migraine-Focused Biotech Has A Headache On Quarterly Losses,Investor's Business Daily
Nov-14-18,Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results,PR Newswire
Nov-15-18,Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant,PR Newswire
Nov-20-18,"Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018",PR Newswire
Nov-26-18,"Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)",PR Newswire
Nov-27-18,"Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes  New Research Emphasizes Economic Growth",GlobeNewswire
Nov-28-18,"Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary",PR Newswire
Nov-29-18,"The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved",Benzinga
Dec-10-18,Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study,PR Newswire
Jan-03-19,"Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Jan-07-19,Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China,PR Newswire
Jan-23-19,"The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoporosis Drug Study",Benzinga
Jan-23-19,Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy,PR Newswire
Feb-04-19,"Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist",PR Newswire
Feb-19-19,Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy,PR Newswire
Feb-20-19,Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole,PR Newswire
Feb-21-19,What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now?,Zacks
